ClinicalTrials.gg
RecruitingNCT06826872Updated Feb 14, 2025

Efficacy and Safety of SPC1001 in Patients With Essential Hypertension

A Phase 2 interventional study of SPC 1001 Mid2 and SPC 2002 in Hypertension, Essential, Cardiovascular Diseases and Cardiology, sponsored by Shin Poong Pharmaceutical Co. Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by Shin Poong Pharmaceutical Co. Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Jun 2024, registered Feb 2025).
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies in Essential Hypertension with a site in Korea, Republic of — 11 open to participants now, 13 under way, 4 of them phase 3. Essential Hypertension · Korea, Republic of.

Planned enrollment
33rd of 86
252 · median 190
Started
2024
with 10 others
Phase 2
16 of 99
2 open now
Primary completion
2025-10
later than 4 of 12 live
Registered
90th of 99
by date
Lead sponsor
3 of 99
Shin Poong Pharmaceutical Co. Ltd.

Among the 99 studies in Essential Hypertension with a site in Korea, Republic of, this one is the 33rd largest by planned enrollment of the 86 interventional ones that give a count, is one of 11 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 90th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

11 of the 99 studies in Essential Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Essential Hypertension with a site in Korea, Republic of, or all of them as a file.
02

Study summary

  • Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses.
  • Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.
  • Exclusion Criteria: Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.
  • Methods: This study is a multicenter, randomized, double-blind, parallel-group, phase 2b clinical trial to evaluate the safety and efficacy of the investigational drug after 8 weeks of administration.

Screening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.

03

Conditions studied

  • Hypertension, Essential
  • Cardiovascular Diseases
  • Cardiology

Keywords

  • blood pressure
  • Low-dose combination therapy
  • candesartan
  • amlodipine
  • indapamide
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.

Exclusion criteria

Exclusion Criteria:

  • Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (estimated)

Study arms

  • Active comparator
    SPC 1001 Mid2

    Drug: SPC 1001 Mid2

  • Active comparator
    SPC2002

    Drug: SPC 1001 Mid2 · Drug: SPC 2002

  • Active comparator
    SPC2003

    Drug: SPC 1001 Mid2 · Drug: SPC 2003

  • Active comparator
    SPC2004

    Drug: SPC 1001 Mid2 · Drug: SPC 2004

Interventions

  • DrugSPC 1001 Mid2

    low-dose combination therapy

  • DrugSPC 2002

    low-dose combination therapy

  • DrugSPC 2003

    low-dose combination therapy

  • DrugSPC 2004

    low-dose combination therapy

06

What researchers measure

Primary outcomes

  1. The primary endpoint was determined by evaluating how mean sitting systolic blood pressure varied between the baseline measurement and week 8.

    Time frame: Change from Baseline in MSSBP at Week 8

07

Study locations

1 of 1 sites recruiting
  • CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea
    Seoul, 06135, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — It is planned to be publicly available in the form of a future journal submission.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Oct 2025, 15 months after the start.

Of 16 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 14, 2025
StartActual
Jun 12, 2024
Primary completionEst.
Oct 8, 2025
CompletionEst.
Dec 30, 2025
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06826872
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Jun 12, 2024
Primary completion
Oct 8, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Feb 14, 2025

Study contacts

YeongJin Jeong, Master
Contact
yjjeong@shinpoong.co.kr
+82 2-2189-3944

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion